xCures Unveils Expanded AI Health Data Platform: Now Supporting All Therapeutic Areas and is Available as SaaS

The company’s platform expansion transforms the value of US healthcare data by harnessing real-time, regulatory-grade data in any therapeutic area to efficiently understand the complex medical histories of patients and drive research through detailed, longitudinal datasets.

OAKLAND, CA – January 31, 2024 xCures, a trailblazer in healthcare technology, announced today the expansion of its AI-assisted medical data platform to support real-time, regulatory-grade data in any therapeutic area. Originally designed as a tool focused specifically on cancer, the company’s platform expansion now serves as a comprehensive tool to collect and understand medical records for any US patient with any condition.

Harnessing AI/ML technology, xCures’ platform gathers records, extracts, and aggregates data, including organizing and structuring clinical, genomic, and imaging information from diverse sources, into a searchable digital record. This solution can help any user looking to quickly find or assess key clinical information about a patient for care-related activities. This integrated approach transforms how medical professionals and researchers can understand complex patients and cohort characteristics

xCures makes this technology available through software licenses to the platform and direct API connections embedded within existing healthcare workflow management platforms.  The system offers a patient-centric, longitudinal perspective crucial for informed decision-making.  

This evolution marks another advancement that will significantly benefit those making data-driven healthcare decisions.  Because the collected data can also be de-identified it can be be available for secondary research;  xCures provides the most comprehensive patient-centric longitudinal data in the form of deidentified real-world datasets that contain comprehensive insights across all providers and care locations. 

“Expanding our AI platform beyond oncology marks a significant milestone in our mission to transform the value of healthcare data,” said Mika Newton, CEO of xCures. “We’re providing access to a software platform that generates precise real-world data at the individual and cohort levels across all diseases that will accelerate groundbreaking research across many fields and directly benefit patients. ”

With its ability to aggregate and interpret diverse medical records quickly and accurately, xCures’ platform is a game-changer for anyone working to access and interpret retrospective and prospective healthcare or real-world data. It facilitates an in-depth understanding of medical patterns and conditions and enhances the scope of clinical trials and research across various diseases. Making this technology available across the healthcare ecosystem as a platform solution transforms the opportunity to leverage US healthcare data.

For more information, visit https://xcures.com/ 

About xCures

Launched in 2018, xCures Inc. operates an AI-assisted platform that automatically retrieves and aggregates medical records from any US care site. Data is extracted and structured within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com or visit http://www.xcures.com.

###

xCures and Aetion® Further Enhance Partnership with Rich Real-World Datasets

Partnership now includes access to five comprehensive oncology datasets, enhancing real-world evidence in cancer research.

In the realm of oncology research, diverse, comprehensive, and fully longitudinal datasets are invaluable. They offer a granular view of patient journeys throughout the US, enabling researchers to draw clinically relevant insights.

These comprehensive datasets are crucial for advancing personalized treatment strategies and improving patient outcomes in cancer care.

The challenge in current oncology outcomes research lies in the fragmentation of patient data across numerous healthcare providers and sites of care. This creates significant gaps in understanding patient outcomes and treatment efficacies. The scattered data landscape hinders the development of robust real-world evidence (RWE) necessary for impactful cancer research.

xCures consolidates and structures clinical, genomic, and imaging data directly from patients’ electronic medical records, healthcare providers, and other sites of care along the patient’s care journey.

The broad, longitudinal, patient-centric view enables researchers and clinicians to access up-to-date and comprehensive information, paving the way for more informed and timely treatment decisions.

In addition to contributing data to support Aetion’s collaboration with the Food and Drug Administration, the new partnership enables Aetion®, a global leader in RWE and analytics, to incorporate xCures’ breast cancer, glioma, melanoma, colorectal cancer, and ovarian/uterine cancer datasets into their Accelerated Access Oncology Program.

“We’re thrilled about this partnership with Aetion,” said Mika Newton, xCures CEO. “It’s a testament to the power of collaborative efforts in advancing oncology research. By bringing our real-time, regulatory-grade, clinical data (RRC) to a broader audience, we’re not just sharing information – we’re empowering a shift towards more effective, patient-centric cancer treatments.”

Wendy Turenne, Senior Vice President, Real World Data & Operations at Aetion, said: “We are delighted to partner with xCures, as their datasets provide a unique lens into the patient’s experience. In combination with Aetion® Substantiate, these data can be analyzed in novel ways and shorten the time to generate and deliver critical insights that will help shape the future of cancer treatment.”

Contact us today for more information on how this partnership can empower your research and development strategies.

About xCures

Since 2018, xCures Inc. has operated an AI-assisted platform that automatically retrieves and aggregates medical records from all US care sites. Data is extracted and structured within 15 minutes to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures provides clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com, or visit http://www.xcures.com.

About Aetion®

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. Aetion’s suite of real-world data analytics applications analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc.

xCures to offer clinical data extraction as a service in AWS Marketplace

AWS cloud configurations will help xCures customers to leverage the company’s robust data gathering and structuring services while maintaining secure, private ownership of their data.

xCures, a trailblazer in healthcare technology is proud to offer its platform as a clinical data extraction service in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS).

The xCures platform is a real-time clinical data and evidence-generation tool. It is designed to securely collect complete, longitudinal medical records from virtually all US sites of care. Further, the platform automates the processing of patient records into both standardized, structured datasets (i.e., the most commonly requested FHIR format resources) and semantic interpretations of patient cases.

The Platform can gather data across care settings (including sendout labs), even when subjects change providers, insurance plans, or locations. The data is structured into de-identifiable, tokenizable representations desired by industry and stored in xCures’ multi-tenant data and evidence generation private cloud platform. This allows clients to transition from having data rights to having data assets.

All structured data is completely source-verifiable (i.e., can be traced to a clinical record) and can be gathered (or refreshed) and analyzed in minutes. The Platform is also equipped with cutting-edge Natural Language Processing (NLP) technology to assist human annotation. This ensures that output data is primed for specialized analyses or applications, even when there are custom abstraction requirements.

Mika Newton, CEO of xCures, expressed his enthusiasm about the AWS Marketplace listing, stating, “By aligning with AWS, we’re reaffirming our commitment to offering clients enhanced security and scalability. By leveraging the power of AWS, our clients can be confident that their data remains shielded by the finest digital and physical security mechanisms.”

This latest offering is a testament to xCures’ unwavering dedication to revolutionizing healthcare data accessibility, management, and security. With the Cures Platform in AWS Marketplace, the future of clinical data use looks brighter than ever.

Visit xCures’ listing in AWS Marketplace to get started; or learn more about xCures and AWS here.

About xCures

Since 2018, xCures Inc. has operated an AI-assisted platform that automatically retrieves and aggregates medical records from all US care sites. Data is extracted and structured, within 15 minutes, to offer a sophisticated view of a patient’s fully longitudinal health journey that encompasses everything from genomics to social determinants of health.

Through a variety of tools and data products, xCures can provide clinically actionable, real-time insights that facilitate clinical research and care for patients, providers, and partners. For more information, contact info@xcures.com.

xCures Partners with the Pancreatic Cancer Action Network (PanCAN)

xCures offers unparalleled access to data and the xINFORM patient portal to accelerate pancreatic cancer research and improve patient care

OAKLAND, CA – xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN).

As part of the agreement, PanCAN’s researchers and grantees will have unparalleled access to xCures’ deidentified Real-time, Regulatory-grade Clinical data. 

This collaboration aims to drive innovations and breakthroughs in pancreatic cancer research by harnessing the power of real-time patient data. xCures database boasts fully longitudinal clinical data from thousands of pancreatic cancer patients, including over 25,000 locations and ~4,000 medical records per patient.

The benefits of this partnership extend beyond the research community. xCures is making their xINFORM patient portal available to PanCAN’s leading Patient Services program.

The state-of-the-art portal aggregates and centralizes patients’ medical records and structures them into a computable format and an easy-to-understand longitudinal timeline. 

The xINFORM portal supports patients in being matched with suitable treatments and clinical programs, obtaining invaluable second opinions.

Sudheer Doss, Ph.D., Chief Business Officer of PanCAN, shared his enthusiasm for the partnership: “We’re always in search of innovative ways to serve our patient community better and accelerate pancreatic cancer research. As part of the comprehensive free services we offer through our PanCAN Patient Services program, this platform can pave the way for identifying optimal treatments and ensuring that our patients receive the best care possible.”

The PanCAN-xCures partnership blends the strengths of both organizations to advance patient outcomes and bolster research capabilities.

“We at xCures are deeply committed to placing patients at the forefront of all our endeavors,” said Mika Newton, CEO of xCures. “This new partnership with PanCan is a testament to our dedication to advancing patient-centric solutions and strengthening our bond with patient advocacy organizations. Together, we will usher in a brighter, more hopeful future for all.”

About xCures

xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. 

The (unstructured) data is aggregated and organized into a powerful, up-to-date care summary that helps cancer patients get the right therapy at the right time. 

The platform’s portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. 

The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. 

For more information, contact info@xcures.com or visit http://www.xcures.com.

About PanCAN

The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive. For 18 years in a row, PanCAN has earned a Four-Star Rating from Charity Navigator – the highest rating an organization can receive. This rating designates PanCAN as an official “Give with Confidence” charity, indicating strong financial health, ongoing accountability and transparency.